Core Viewpoint - Merus N.V. is participating in the 2025 Wells Fargo Healthcare Conference, highlighting its focus on innovative oncology therapies [1]. Company Overview - Merus N.V. specializes in developing full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics® [3]. - The company’s products, including Biclonics®, Triclonics®, and ADClonics®, are designed to have characteristics similar to conventional human monoclonal antibodies, such as long half-life and low immunogenicity [3]. Event Details - Bill Lundberg, M.D., President and CEO of Merus, will engage in a fireside chat at the conference on September 4, 2025, at 3:45 p.m. ET [1]. - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2].